Answers are grounded in this paper and cite their sources.
Amyloid beta protein 40 (Abeta40) and 42 (Abeta42), major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma. The levels of CSF Abeta40 and beta42(43) show a U-shaped natural course in normal aging. The increase of Abeta42(43) over 60 years of age is inhibited in Alzheimer's disease (AD). This specific alteration of CSF Abeta42(43) correlates with Abeta deposits in the AD brain providing a biological basis for a biomarker of AD. In the GTT2 study, assays of the CSF Abeta ratio [(Abeta40/ Abeta42(43)] showed a diagnostic sensitivity (59%) specificity (88%) The levels of the Abeta ratio increased from early to late stages of AD. Combination assays of CSF tau and Abeta ratio provided further efficient diagnostic sensitivity (81%) reliability of the assay may prompt worldwide usage of these CSF biomarkers for Alzheimer's patients.
No takes yet. Share an insight, caveat, or question.
Shoji et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: